PL3715367T3 - Białko fuzyjne zawierające białko il-2 i białko cd80 oraz jego zastosowanie - Google Patents
Białko fuzyjne zawierające białko il-2 i białko cd80 oraz jego zastosowanieInfo
- Publication number
- PL3715367T3 PL3715367T3 PL19862449.6T PL19862449T PL3715367T3 PL 3715367 T3 PL3715367 T3 PL 3715367T3 PL 19862449 T PL19862449 T PL 19862449T PL 3715367 T3 PL3715367 T3 PL 3715367T3
- Authority
- PL
- Poland
- Prior art keywords
- protein
- fusion
- fusion protein
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title 2
- 102000004169 proteins and genes Human genes 0.000 title 2
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180110698 | 2018-09-17 | ||
| KR20190001867 | 2019-01-07 | ||
| US201962832013P | 2019-04-10 | 2019-04-10 | |
| KR20190053436 | 2019-05-08 | ||
| PCT/KR2019/011928 WO2020060122A1 (ko) | 2018-09-17 | 2019-09-16 | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3715367T3 true PL3715367T3 (pl) | 2024-09-02 |
Family
ID=69887592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19862449.6T PL3715367T3 (pl) | 2018-09-17 | 2019-09-16 | Białko fuzyjne zawierające białko il-2 i białko cd80 oraz jego zastosowanie |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US11492384B2 (pl) |
| EP (2) | EP4403635A3 (pl) |
| JP (2) | JP7085644B2 (pl) |
| KR (2) | KR102201086B1 (pl) |
| CN (2) | CN111971295B (pl) |
| AU (1) | AU2019343850B2 (pl) |
| CA (1) | CA3086486A1 (pl) |
| CL (1) | CL2020001872A1 (pl) |
| DK (1) | DK3715367T3 (pl) |
| ES (1) | ES2985387T3 (pl) |
| FI (1) | FI3715367T3 (pl) |
| HU (1) | HUE068059T2 (pl) |
| IL (1) | IL275592B (pl) |
| MX (1) | MX2020007072A (pl) |
| PE (1) | PE20201418A1 (pl) |
| PH (1) | PH12020551026A1 (pl) |
| PL (1) | PL3715367T3 (pl) |
| PT (1) | PT3715367T (pl) |
| SG (1) | SG11202005873QA (pl) |
| TW (2) | TWI755630B (pl) |
| WO (1) | WO2020060122A1 (pl) |
| ZA (1) | ZA202003645B (pl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7461741B2 (ja) * | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| PL3715367T3 (pl) * | 2018-09-17 | 2024-09-02 | Gi Innovation, Inc. | Białko fuzyjne zawierające białko il-2 i białko cd80 oraz jego zastosowanie |
| HUE070131T2 (hu) | 2019-11-20 | 2025-05-28 | Gi Cell Inc | Kompozíció természetes ölõsejtek tenyésztésére és eljárás természetes ölõsejtek elõállítására ennek alkalmazásával |
| JP7543404B2 (ja) * | 2019-11-20 | 2024-09-02 | ジーアイ・セル・インコーポレイテッド | Ｔ細胞培養用培地組成物及びこれを用いたｔ細胞の培養方法 |
| US20230014358A1 (en) * | 2019-11-27 | 2023-01-19 | Gi Cell, Inc. | Composition for anticancer treatment, comprising nk cells and fusion protein which comprises il-2 protein and cd80 protein |
| CN114746544A (zh) * | 2019-11-27 | 2022-07-12 | 吉爱希公司 | 用于治疗癌症的、包含含有il-2蛋白和cd80蛋白的融合蛋白与自然杀手细胞的药物组合物 |
| EP4122953A4 (en) * | 2020-03-18 | 2023-08-23 | GI Innovation, Inc. | FUSION PROTEIN COMPRISING AN IL-2 PROTEIN AND A CD80 PROTEIN AND USES THEREOF |
| CN115666522B (zh) | 2020-03-18 | 2025-05-27 | Gi医诺微新 | 包含il-2蛋白和cd80蛋白的融合蛋白制剂 |
| AU2021239772A1 (en) | 2020-03-18 | 2022-09-15 | Gi Innovation, Inc. | Pharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug |
| IL295826B2 (en) * | 2020-03-31 | 2025-11-01 | Hanmi Pharmaceutical Co Ltd | Novel immunostimulating il-2 analogs |
| CN115943165A (zh) * | 2020-05-25 | 2023-04-07 | 北京比洋生物技术有限公司 | Fc-CD80融合蛋白和其缀合物以及它们的用途 |
| KR102373965B1 (ko) * | 2020-06-05 | 2022-03-15 | (주)지아이이노베이션 | Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 |
| JP7814329B2 (ja) * | 2020-06-30 | 2026-02-16 | ジーアイ イノベーション， インコーポレイテッド | 抗ｌａｇ－３抗体とｉｌ－２とを含む融合タンパク質及びその使用 |
| MX2022016532A (es) * | 2020-07-02 | 2023-04-12 | Inhibrx Inc | Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos. |
| JP2023540296A (ja) * | 2020-08-31 | 2023-09-22 | ジーアイ・セル・インコーポレイテッド | ＩＬ１５タンパク質、ＩＬ１５受容体アルファタンパク質、Ｆｃドメイン及びＩＬ２タンパク質を含む融合タンパク質並びにその用途 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4259648A4 (en) * | 2020-12-08 | 2025-03-26 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Chimeric anti-EGFR antigen receptors |
| US20240392004A1 (en) * | 2021-03-10 | 2024-11-28 | Immunowake Inc. | Immunomodulatory molecules and uses thereof |
| WO2022057696A2 (zh) * | 2021-09-08 | 2022-03-24 | 中南大学湘雅医院 | 一种重组蛋白的编码序列、重组蛋白及其单克隆抗体的制备方法 |
| KR20230168273A (ko) * | 2022-06-03 | 2023-12-13 | (주)지아이이노베이션 | 항-tigit 항체를 포함하는 이중 특이적 항체 및 이의 용도 |
| EP4545562A4 (en) * | 2022-06-22 | 2025-10-01 | Gi Innovation Inc | FUSION PROTEIN COMPRISING AN ANTI-CD73 ANTIBODY AND IL-2, AND USE THEREOF |
| KR102669111B1 (ko) * | 2022-09-20 | 2024-06-10 | 주식회사 지아이바이옴 | 락토바실러스 플란타룸 균주의 병용 요법 및 이를 이용한 암 치료 방법 |
| TW202421176A (zh) | 2022-09-20 | 2024-06-01 | 南韓商Ｇｉ生物群系公司 | 植物乳桿菌菌株的組合療法以及使用其的癌症治療方法 |
| CN115850436B (zh) * | 2022-10-14 | 2026-02-03 | 海徕科(北京)生物技术有限公司 | 白介素2突变体及其应用 |
| WO2025063755A1 (ko) * | 2023-09-20 | 2025-03-27 | 주식회사 에스엘바이젠 | 항암 dna 백신 및 면역반응-증진용 융합단백질을 포함하는 신규 암 치료제 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0119621A1 (en) * | 1983-03-21 | 1984-09-26 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Interleukin-2 |
| CN86104525A (zh) * | 1985-07-31 | 1987-02-25 | 武田药品工业株式会社 | 人类白细胞介素-2的分析方法和试剂 |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| GB9810999D0 (en) | 1998-05-21 | 1998-07-22 | Goken Joop | Materials and methods relating to the expression of genes |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| WO2003015697A2 (en) | 2001-08-13 | 2003-02-27 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
| ATE542137T1 (de) | 2001-12-04 | 2012-02-15 | Merck Patent Gmbh | Immunocytokine mit modulierter selektivität |
| CU23229A1 (es) | 2002-05-10 | 2007-09-26 | Ct Ingenieria Genetica Biotech | ANTAGONISTA QUIMéRICO ANTH1 |
| EP1723251A4 (en) * | 2004-03-05 | 2008-04-23 | Novartis Vaccines & Diagnostic | IN VITRO TEST SYSTEM FOR THE FORECASTING THE COMPATIBILITY OF A PATIENT AGAINST THERAPEUTICS |
| EP2402754B2 (en) * | 2006-03-06 | 2023-07-26 | Amunix Operating Inc. | Unstructured recombinant polymers and uses thereof |
| WO2008003473A2 (en) | 2006-07-06 | 2008-01-10 | Merck Patent Gmbh | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| MX2010001684A (es) * | 2007-08-15 | 2010-04-21 | Amunix Inc | Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos. |
| CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| HUE029139T2 (hu) * | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US8956619B2 (en) | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| BR112015022119A2 (pt) | 2013-03-15 | 2017-08-29 | Abbvie Biotherapeutics Inc | Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento |
| CA2951604A1 (en) * | 2014-08-29 | 2016-03-03 | Pablo Umana | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 |
| JP6936221B2 (ja) * | 2015-11-02 | 2021-09-15 | ファイブ プライム セラピューティクス， インコーポレイテッド | Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用 |
| CN115073581A (zh) * | 2016-05-04 | 2022-09-20 | 美国安进公司 | 用于扩增t调节性细胞的白细胞介素-2突变蛋白 |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| US9567399B1 (en) * | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| EP4201953A1 (en) | 2017-04-03 | 2023-06-28 | F. Hoffmann-La Roche AG | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| PL3715367T3 (pl) * | 2018-09-17 | 2024-09-02 | Gi Innovation, Inc. | Białko fuzyjne zawierające białko il-2 i białko cd80 oraz jego zastosowanie |
-
2019
- 2019-09-16 PL PL19862449.6T patent/PL3715367T3/pl unknown
- 2019-09-16 CN CN201980025699.8A patent/CN111971295B/zh active Active
- 2019-09-16 HU HUE19862449A patent/HUE068059T2/hu unknown
- 2019-09-16 KR KR1020190113659A patent/KR102201086B1/ko active Active
- 2019-09-16 JP JP2020562067A patent/JP7085644B2/ja active Active
- 2019-09-16 ES ES19862449T patent/ES2985387T3/es active Active
- 2019-09-16 SG SG11202005873QA patent/SG11202005873QA/en unknown
- 2019-09-16 DK DK19862449.6T patent/DK3715367T3/da active
- 2019-09-16 FI FIEP19862449.6T patent/FI3715367T3/fi active
- 2019-09-16 US US16/959,312 patent/US11492384B2/en active Active
- 2019-09-16 MX MX2020007072A patent/MX2020007072A/es unknown
- 2019-09-16 EP EP24175556.0A patent/EP4403635A3/en active Pending
- 2019-09-16 WO PCT/KR2019/011928 patent/WO2020060122A1/ko not_active Ceased
- 2019-09-16 CN CN202410942368.3A patent/CN118725141A/zh active Pending
- 2019-09-16 PE PE2020000980A patent/PE20201418A1/es unknown
- 2019-09-16 CA CA3086486A patent/CA3086486A1/en active Pending
- 2019-09-16 EP EP19862449.6A patent/EP3715367B1/en active Active
- 2019-09-16 AU AU2019343850A patent/AU2019343850B2/en active Active
- 2019-09-16 PT PT198624496T patent/PT3715367T/pt unknown
- 2019-09-17 TW TW108133398A patent/TWI755630B/zh active
- 2019-09-17 TW TW110122590A patent/TWI824258B/zh active
-
2020
- 2020-06-17 ZA ZA2020/03645A patent/ZA202003645B/en unknown
- 2020-06-22 IL IL275592A patent/IL275592B/en unknown
- 2020-06-30 PH PH12020551026A patent/PH12020551026A1/en unknown
- 2020-07-14 CL CL2020001872A patent/CL2020001872A1/es unknown
-
2021
- 2021-01-05 KR KR1020210000775A patent/KR102558191B1/ko active Active
-
2022
- 2022-04-21 JP JP2022070213A patent/JP7569820B2/ja active Active
- 2022-08-01 US US17/878,664 patent/US12291555B2/en active Active
- 2022-08-01 US US17/878,703 patent/US12286464B2/en active Active
-
2025
- 2025-04-01 US US19/097,579 patent/US20250230212A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275592B (en) | A fusion protein containing the il-2 protein and the cd80 protein and its uses | |
| EP3623389A4 (en) | FUSION PROTEIN WITH TGF RECEPTOR AND ITS MEDICAL USES | |
| EP3737666A4 (en) | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES | |
| EP3743438A4 (en) | CYTOKI FUSION PROTEINS | |
| SG11202012004SA (en) | Rna-targeting fusion protein compositions and methods for use | |
| EP3481413A4 (en) | FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| EP3147298A4 (en) | Pd-l1 fusion protein and use thereof | |
| EP3122783A4 (en) | Novel recombinant bi-functional fusion proteins, preparation and use thereof | |
| EP3565828B8 (en) | A sirpalpha-4-1bbl fusion protein and methods of use thereof | |
| ZA202103259B (en) | Modified cas9 protein, and use thereof | |
| SG11202104912SA (en) | Fusion protein and use thereof | |
| SG11202101227TA (en) | Novel crispr-associated protein and use thereof | |
| EP3831945A4 (en) | PROTEIN HETERODIMER AND ITS USE | |
| EP3836959A4 (en) | ANTI-ANGIOGENESIS FUSION PROTEIN AND USES ITS | |
| ZA202000595B (en) | Novel therapeutic enzyme fusion protein and use thereof | |
| ZA201907063B (en) | Insecticidal proteins and methods for their use | |
| EP3849599A4 (en) | Pneumococcal fusion protein vaccines | |
| IL263842A (en) | Tatk -cdkl5 fusion proteins, compositions, formulations, and use thereof | |
| IL279057A (en) | Antimicrobial fusion proteins containing endolysin and their uses | |
| ZA202102533B (en) | Fusion protein | |
| EP3101035A4 (en) | Bifunctional fusion protein, preparation method therefor, and use thereof | |
| IL287601A (en) | Variant cd80 proteins and their uses | |
| EP3856895A4 (en) | AUTOLOGOUS BIHAPTENIZED VACCINES AND THEIR USES | |
| EP3897691A4 (en) | IL-10 CONTAINING VACCINES AND THEIR USES | |
| EP3425054C0 (en) | CYTOCHROME MUTANT PROTEIN AND ITS USE |